Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T‐cell lymphoma in children and adolescents
Open Access
- 23 January 2021
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (5) , e28901
Abstract
Purpose: As extranodal natural killer/T‐cell lymphoma (ENKTL) occurs rarely in children and adolescents, standardized therapy is yet to be determined. This study aimed to describe the clinical features and determine the optimal chemotherapy regimen for childhood ENKTL.Methods: The treatment outcomes of radiotherapy combined with asparaginase‐based (P‐GEMOX or P‐GMED) or asparaginase‐absent chemotherapy regimens (CHOP, EPOCH, or NHL‐BFM‐90/95) in patients aged ≤18 years with newly diagnosed ENKTL from December 2006 to December 2018 were compared.Results: Among the 34 patients included in the study, 21 had stage I/II disease. The overall response rates of chemotherapy with or without asparaginase were 85.0% and 78.6%, respectively. With a median follow‐up of 54 months, the 5‐year event‐free survival (EFS) rates of patients with stage I/II and III/IV disease were 66.2 ± 11.3% and 26.0 ± 12.8%, respectively (P = .027). In stage III/IV patients treated with asparaginase‐based or asparaginase‐absent regimens, the 5‐year EFS rates were 40.0 ± 17.4% and 0%, respectively (P = .236). The 5‐year EFS rates of stage III/IV patients who received or did not receive hematopoietic stem cell transplant were 66.7 ± 27.2% and 11.1 ± 10.5%, respectively (P = .054). In addition, chemotherapy‐associated side effects were significantly less in patients treated with asparaginase‐based regimens as compared to asparaginase‐absent regimens in this cohort.Conclusion: P‐GEMOX and P‐GMED regimens are effective and safe for treating childhood ENKTL.Keywords
This publication has 37 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphomaInvestigational New Drugs, 2012
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study GroupBlood, 2012
- Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma StudyJournal of Clinical Oncology, 2009
- Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescentsBlood, 2009
- Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcomeAnnals of Oncology, 2009
- Retrospective analysis of non‐anaplastic peripheral T‐cell lymphoma in pediatric patients in JapanPediatric Blood & Cancer, 2009
- Non‐anaplastic peripheral t‐cell lymphoma in childhood and adolescence: A Children's Oncology Group studyPediatric Blood & Cancer, 2008
- Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell LymphomaJournal of Clinical Oncology, 2006
- Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: Sensitivity and specificity of the ann arbor staging procedure criteriaAmerican Journal of Hematology, 1989